CCA
BSTG

Catalyst Capital Advisors’s Biostage, Inc. Common Stock BSTG Stock Holding History

Catalyst Capital Advisors’s Portfolio BSTG Stock Details BSTG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-6,120
Closed -$56K – 440
2014
Q1 		$56K Hold
6,120
– – 0.01% 305
2013
Q4 		$29K Buy
+6,120
New +$28.6K 0.01% 250

Other funds holding BSTG

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HSA
Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Catalyst Capital Advisors's BSTG Position: Q2 2014 in Review

Catalyst Capital Advisors sold out of Biostage, Inc. Common Stock (BSTG) in Q2 2014, closing a stake of 6,120 shares — an estimated $56K sold.

Catalyst Capital Advisors first reported a position in BSTG in Q4 2013 and held it in 2 quarters. The position peaked at $56K in Q1 2014. 53 funds tracked by Wall St. Rank hold BSTG as of Q2 2014.

  • Catalyst Capital Advisors reported no remaining Biostage, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • Catalyst Capital Advisors sold 6,120 Biostage, Inc. Common Stock shares in Q2 2014, an estimated $56K.
  • Catalyst Capital Advisors first reported a position in Biostage, Inc. Common Stock in Q4 2013 and held it in 2 quarters.
  • Catalyst Capital Advisors's Biostage, Inc. Common Stock position peaked at $56K in Q1 2014.
  • 53 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q2 2014.

Based on Catalyst Capital Advisors's 13F filing for Q2 2014, filed 12 Aug 2014.